Amgen, FTC said there are no ongoing talks, though open to settlement over Horizon
hapabapa
Amgen (NASDAQ:AMGN) and the Federal Trade Commission said there are no ongoing talks to try to come to a settlement over the antitrust's regulators block of the $28 billion Horizon Therapeutics (NASDAQ:HZNP) deal. Horizon shares ticked up 0.1%.
Both Amgen and the FTC said that there have been discussions in the past, according to a short scheduling hearing with the FTC's Adminstrative Law Judge on Wednesday.
ALJ Judge Michael Chappell urged the parties to enter talks and the companies said they were open to the possibility. Amgen outside attorney David Marriott spoke on behalf of the biotech comopany.
Amgen (AMGN) last month said it won't close the deal before Oct. 31 or the second business day after the court rules on the FTC's request to block the deal. U.S. District Judge John Kness initially set a hearing for September on the FTC's efforts to block the combination.
The FTC filed its lawsuit with the in-house Administrative Law Judge to block the transaction last month. 
CNBC's David Faber last month reported that the Amgen (AMGN) and Horizon (HZNP) had talks with the FTC, though they didn't lead to a settlement.
Amgen (AMGN) agreed to acquire Horizon Therapeutics (HZNP) for $116.50 a share in cash in December, valuing the Ireland-based biotech at nearly $27.8 billion.
More on Horizon Therapeutics, Amgen

iRobot, Seagen, Horizon gain amid Microsoft win in Activision case
Six states join FTC lawsuit to block Amgen's planned purchase of Horizon
Anticompetitive Behavior At United Therapeutics, Regeneron, And The FTC
FTC Surprise Challenge Of Amgen's Acquisition Of Horizon Therapeutics